Repligen Co. (NASDAQ:RGEN) Director Thomas F. Ryan, Jr. sold 1,763 shares of the company’s stock in a transaction on Monday, November 5th. The shares were sold at an average price of $65.75, for a total value of $115,917.25. Following the sale, the director now owns 3,225 shares of the company’s stock, valued at $212,043.75. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Shares of RGEN opened at $67.98 on Thursday. Repligen Co. has a 12-month low of $29.56 and a 12-month high of $70.50. The stock has a market capitalization of $2.98 billion, a price-to-earnings ratio of 98.52, a PEG ratio of 5.33 and a beta of 0.74.
Repligen (NASDAQ:RGEN) last issued its earnings results on Thursday, November 1st. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.18 by $0.02. Repligen had a return on equity of 5.39% and a net margin of 12.61%. The business had revenue of $49.53 million during the quarter, compared to analysts’ expectations of $46.69 million. During the same quarter in the prior year, the firm earned $0.15 EPS. The business’s revenue for the quarter was up 35.4% compared to the same quarter last year. Equities analysts forecast that Repligen Co. will post 0.73 earnings per share for the current year.
RGEN has been the subject of a number of recent analyst reports. William Blair reiterated an “outperform” rating on shares of Repligen in a research report on Friday, November 2nd. BidaskClub cut Repligen from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 31st. Zacks Investment Research cut Repligen from a “buy” rating to a “hold” rating in a report on Wednesday. ValuEngine raised Repligen from a “buy” rating to a “strong-buy” rating in a report on Tuesday, October 23rd. Finally, Citigroup boosted their price target on Repligen from $45.00 to $56.00 and gave the stock a “buy” rating in a report on Friday, July 20th. Three investment analysts have rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $59.33.
Repligen Company Profile
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.
Featured Article: Why do companies issue stock splits?
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.